Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioGeneration closes third fund

European VC BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE